84 related articles for article (PubMed ID: 6280740)
1. RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers.
Burnier M; Turini GA; Brunner HR; Porchet M; Kruithof D; Vukovich RA; Gavras H
Br J Clin Pharmacol; 1981 Dec; 12(6):893-9. PubMed ID: 6280740
[TBL] [Abstract][Full Text] [Related]
2. CGS 13945: a new orally active angiotensin-converting enzyme inhibitor in normal volunteers.
Jacot des Combes B; Turini GA; Brunner HR; Porchet M; Chen DS; Sen S
J Cardiovasc Pharmacol; 1983; 5(4):511-6. PubMed ID: 6193344
[TBL] [Abstract][Full Text] [Related]
3. Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers.
Schaller MD; Nussberger J; Waeber B; Bussien JP; Turini GA; Brunner H; Brunner HR
Eur J Clin Pharmacol; 1985; 28(3):267-72. PubMed ID: 2988972
[TBL] [Abstract][Full Text] [Related]
4. A potent converting enzyme inhibitor CGS 13928C. Drug profile in normal volunteers.
Schaller MD; Brunner DB; Nussberger J; Turini GA; Sen SB; Chen D; Waeber B; Brunner HR
Eur J Clin Pharmacol; 1984; 26(4):419-24. PubMed ID: 6329767
[TBL] [Abstract][Full Text] [Related]
5. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.
Bussien JP; Nussberger J; Porchet M; Waeber B; Brunner HR; Perisic M; Tansey MJ; Bomm M; Hajdu P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Mar; 329(1):63-9. PubMed ID: 2987705
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
Biollaz J; Brunner HR; Gavras I; Waeber B; Gavras H
J Cardiovasc Pharmacol; 1982; 4(6):966-72. PubMed ID: 6185790
[TBL] [Abstract][Full Text] [Related]
7. Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers.
Fasanella d'Amore T; Bussien JP; Nussberger J; Waeber B; Turini GA; Brunner HR; Kler L; Francis RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):26-31. PubMed ID: 2434790
[TBL] [Abstract][Full Text] [Related]
8. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I.
Biollaz J; Burnier M; Turini GA; Brunner DB; Porchet M; Gomez HJ; Jones KH; Ferber F; Abrams WB; Gavras H; Brunner HR
Clin Pharmacol Ther; 1981 May; 29(5):665-70. PubMed ID: 6260419
[TBL] [Abstract][Full Text] [Related]
9. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers.
Nussberger J; Fasanella d'Amore T; Porchet M; Waeber B; Brunner DB; Brunner HR; Kler L; Brown AN; Francis RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):39-44. PubMed ID: 2434792
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".
Gavras H; Biollaz J; Waeber B; Brunner HR; Gavras I; Davies RO
Lancet; 1981 Sep; 2(8246):543-7. PubMed ID: 6116000
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
[TBL] [Abstract][Full Text] [Related]
12. A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man.
Manhem PJ; Ball SG; Morton JJ; Murray GD; Leckie BJ; Fraser R; Robertson JI
Br J Clin Pharmacol; 1985 Jul; 20(1):27-35. PubMed ID: 2992562
[TBL] [Abstract][Full Text] [Related]
13. A specific orally active inhibitor of angiotensin-converting enzyme in man.
Ferguson RK; Turini GA; Brunner HR; Gavras H; McKinstry DN
Lancet; 1977 Apr; 1(8015):775-8. PubMed ID: 66571
[TBL] [Abstract][Full Text] [Related]
14. Effects of the oral converting enzyme inhibitor SQ 14225 in experimental high output failure.
Williams GM; Davis JO; Freeman RH; DeForrest JM; Seymour AA; Rowe BP
Am J Physiol; 1979 Jun; 236(6):F541-5. PubMed ID: 220888
[TBL] [Abstract][Full Text] [Related]
15. Plasma angiotensin-(1-8) octapeptide measurement to assess acute angiotensin-converting enzyme inhibition with captopril administered parenterally to normal subjects.
Nussberger J; Waeber G; Waeber B; Bidiville J; Brunner HR
J Cardiovasc Pharmacol; 1988 Jun; 11(6):716-21. PubMed ID: 2457768
[TBL] [Abstract][Full Text] [Related]
16. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects.
Bussien JP; d'Amore TF; Perret L; Porchet M; Nussberger J; Waeber B; Brunner HR
Clin Pharmacol Ther; 1986 May; 39(5):554-8. PubMed ID: 3516512
[TBL] [Abstract][Full Text] [Related]
17. The present molecules of converting enzyme inhibitors.
Brunner HR; Nussberger J; Waeber B
J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S2-11. PubMed ID: 2580170
[TBL] [Abstract][Full Text] [Related]
18. The effect of enalapril (MK421), an angiotensin converting enzyme inhibitor, on the conscious pregnant ewe and her foetus.
Broughton Pipkin F; Wallace CP
Br J Pharmacol; 1986 Mar; 87(3):533-42. PubMed ID: 3026539
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.
Azizi M; Guyene TT; Chatellier G; Ménard J
J Hypertens; 1994 Apr; 12(4):419-27. PubMed ID: 8064166
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular pressor reactivity after chronic converting enzyme inhibition.
Bernasconi M; Marone C; Beretta-Piccoli C; Lepori G; Shaw S; Weidmann P
Am J Hypertens; 1991 Apr; 4(4 Pt 1):348-55. PubMed ID: 1829371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
